Singhal sees significant opportunity for diagnositics players such as Dr Lal Path Labs, Thyrocare and SRL. Organised players are already gaining market share and companies which maintain quality standards will definitely do well, he says.

Won't see any transfer of debt in Fortis re-jig: CEO

The name of Fortis Malar will subsequently be changed to SRK. CNBC-TV18's Varinder Bansal caught up with Bhavdeep Singh, CEO, Fortis Healthcare, to get more details.

Fortis to get a makeover, demerge diagnostics business

The board of directors of Fortis Healthcare on Friday approved the demerger of its diagnostics business. Fortis will include its diagnostics business into Fortis Malar Hospitals which will later be renamed SRL, the company said in a filing to BSE.